Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
90 hedge funds and large institutions have $375M invested in Chinook Therapeutics, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 38 increasing their positions, 20 reducing their positions, and 9 closing their positions.
518% more call options, than puts
Call options by funds: $674K | Put options by funds: $109K
90% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 20
89% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 9
24% more capital invested
Capital invested by funds: $301M → $375M (+$73.7M)
10% more funds holding
Funds holding: 82 → 90 (+8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HMC
Harvard Management Company
Boston,
Massachusetts
|
+$77.5M |
| 2 |
State Street
Boston,
Massachusetts
|
+$8.88M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$4.05M |
| 4 |
BlackRock
New York
|
+$3.18M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ORI
Oak Ridge Investments
Chicago,
Illinois
|
-$2.96M |
| 2 |
NC
Nexthera Capital
New York
|
-$1.77M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$1.37M |
| 4 |
CM
Crestline Management
Fort Worth,
Texas
|
-$1.25M |
| 5 |
Jennison Associates
New York
|
-$909K |
KDNY Hedge Fund Activity: Q3 2017 in Review
90 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q3 2017, worth a combined $375M — up 24% from $301M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new KDNY positions and 9 closed out — a net gain of 8 holders — while 38 added to existing stakes and 20 trimmed.
The largest buyer was Harvard Management Company, opening a new position worth an estimated $77.5M. The largest seller was Oak Ridge Investments, cutting an estimated $2.96M.
- 90 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q3 2017, up from 82 in Q2 2017.
- Funds reported $375M of Chinook Therapeutics, Inc. Common Stock stock for Q3 2017, up 24% quarter-over-quarter.
- 17 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q3 2017 and 9 closed out, a net change of +8 holders.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q3 2017 was Harvard Management Company, an estimated $77.5M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q3 2017 was Oak Ridge Investments, an estimated $2.96M sold.
Based on aggregated 13F filings for Q3 2017.